At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 217 enrolled
Drug / intervention
Adalimumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Double-Blind, Randomized, Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating Adalimumab and Placebo for Nail Psoriasis and Plaque Psoriasis. Completed, enrolled 217 participants.
Detailed Summary
This study is being conducted to assess the safety and efficacy of adalimumab in participants with nail psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNail Psoriasis, Plaque Psoriasis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 2013
Enrollment StartJan 2014
Primary CompletionOct 2015
Study CompletionApr 2016
TodayJul 2026
First PostedDec 20, 2013
Enrollment StartJan 1, 2014
Primary CompletionOct 1, 2015
Study CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 12.5 years ago
Interventions
Adalimumabbiological
Placeboother